The opioid epidemic in North America: Implications for Australia


The opioid epidemic in North America has attracted considerable international concern because of the scale of the problem and the high rate of overdose deaths. This paper explores the factors that have contributed to the opioid epidemic in the United States and Canada, and reviews the current situation in Australia.There is little evidence that Australia is on the same trajectory as the United States or Canada, or that fentanyl, particularly illicit fentanyl, has penetrated the Australian drug market as it has overseas. There is, however, evidence of an increase in harm associated with pharmaceutical opioids and heroin, despite a fall in heroin use.This paper highlights the importance of being vigilant about the potential for similar problems in Australia, and continuing to monitor key indicators of opioid availability, use and harm. Responses to opioid misuse and overdose must be relevant to the Australian context.


URLs correct as at March 2024

Alexander GC, Frattaroli S & Gielen AC 2015. The prescription opioid epidemic: An evidence-based approach. Baltimore: John Hopkins Bloomberg School of Public Health

Alpert A, Powell D & Pacula RL 2018. Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids. American Economic Journal: Economic Policy 10(4): 1–35

Australian Bureau of Statistics 2017. Causes of death, Australia, 2016. ABS cat. no. 3303.0. Canberra: Australian Bureau of Statistics.

Australian Criminal Intelligence Commission (ACIC) 2018a. Illicit drug data report 2016–17. Canberra: ACIC.

Australian Criminal Intelligence Commission 2018b. National Wastewater Drug Monitoring Program: Report 6, December 2018. Canberra: ACIC.

Australian Institute of Health and Welfare (AIHW) 2018a. Opioid harm in Australia and comparisons between Australia and Canada. AIHW cat. no. HSE 210. Canberra: AIHW

Australian Institute of Health and Welfare 2018b. Alcohol and other drug treatment services in Australia 2016–17. AIHW cat. no. HSE 207. Canberra: AIHW

Australian Institute of Health and Welfare 2017a. Non-medical use of pharmaceuticals: Trends, harms and treatment: 2006–07 to 2015–16. AIHW cat. no. HSE 195. Canberra: AIHW

Australian Institute of Health and Welfare 2017b. National Drug Strategy Household Survey 2016: Detailed findings. AIHW cat. no. PHE 214. Canberra: AIHW

Ball M, Broadhurst R & Trivedi H 2019. How much fentanyl is available on the darknet? Statistical Bulletin no. 18. Canberra: Australian Institute of Criminology.

Barratt M, Latimer J, Jauncey M, Tay E & Nielsen S 2018. Urine drug screening for early detection of unwitting use of fentanyl and its analogues among people who inject heroin in Sydney, Australia. Drug and Alcohol Review 37(7): 847–850

Beletsky L & Davis CS 2017. Today’s fentanyl crisis: Prohibition’s Iron Law, revisited. International Journal of Drug Policy 46: 156–159

Belzak L & Halverson J 2018. The opioid crisis in Canada: A national perspective. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice 38(6): 224–233

Boddiger D 2006. Fentanyl-laced street drugs “kill hundreds”. The Lancet 368: 569–570

Brinkley-Rubinstein L, Macmadu A, Marshall BDL, Heise A, Ranapurwala SI, Rich JD and Green TC 2018. Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015. Drug and Alcohol Dependence 185: 189–191

Campbell G, Lintzeris N, Gisev N, Larance B, Pearson S & Degenhardt L 2019. Regulatory and other responses to the pharmaceutical opioid problem. MJA 210(1): 6–8

Canadian Centre on Substance Use and Addiction 2017. Joint statement of action to address the opioid crisis: A Collective response: Annual report 2016–2017. Ottawa: Canadian Centre on Substance Use and Addiction

Christie C, Baker C, Cooper R, Kennedy PJ, Madras B & Bondi P 2018. The president’s commission on combating drug addiction and the opioid crisis. Washington, DC: White House.

Ciccarone D 2017. Fentanyl in the US heroin supply: A rapidly changing risk environment. International Journal of Drug Policy 46: 107–111

Dasgupta N, Beletsky L & Ciccarone D 2018. Opioid crisis: No easy fix to its social and economic determinants. AJPH Perspectives 108(2): 182–186

Dhalla IA, Persaud N & Juurlink DN 2011. Facing up to the prescription opioid crisis. BMJ 2011; 343:d5142

Donroe JH, Socias ME & Marshall BD 2018. The deepening opioid crisis in North America: Historical and current solutions. Current Addiction Reports 5(4): 454–463

Fink DS et al. 2018. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review. Annals of Internal Medicine 168(11): 783–790

Gallagher R 2018. Opioid-related harms: Simplistic solutions to the crisis ineffective and cause collateral damage. Health Services Insights 11: 1–3

Geddes L, Iversen J, Memedovic S & Maher L 2018. Intravenous fentanyl use among people who inject drugs in Australia. Drug and Alcohol Review 37 supplement 1. DOI: 10.1111/dar.12668

Gilbert M & Dasgupta N 2017. Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains. International Journal of Drug Policy 46: 160–167

Gisev N et al. 2018a. Current opioid access, use, and problems in Australasian jurisdictions. Current Addiction Reports 5: 464–472

Gisev N et al. 2018b. A nationwide study of the extent and factors associated with fentanyl use in Australia. Research in Social and Administrative Pharmacy 14: 303–308

Hedegaard H, Miniño AM & Warner M 2018. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief no. 329. Hyattsville, MD: National Center for Health Statistics

Hedegaard H, Trinidad JP & Warner M 2018. Drugs most frequently involved in drug overdose deaths: United States 2011–2016. National Vital Statistics Reports 67(9). US Department of Health and Human Services

Hulme S, Bright D & Nielsen S 2018. The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. Drug and Alcohol Dependence 186: 242–256

Kertesz SG 2017. Turning the tide or riptide? The changing opioid epidemic. Substance Abuse 38(1): 3–8

Kolodny A et al. 2015. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annual Review of Public Health 36: 559–574

Larance B et al. 2018. Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. Drug and Alcohol Review 37 supplement 1: S203–S205. DOI: 10.1111/dar.12617

Latimer J, Ling S, Flaherty I, Jauncey M & Salmon AM 2016. Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy 37: 111–114

Martins SS, Santaella-Tenorio J, Marshall BDL, Maldonado A & Cerdá M 2015. Racial/ethnic differences in trends in heroin use and heroin-related risk behaviours among nonmedical prescription opioid users. Drug and Alcohol Dependence 151: 278–283

Mayer S, Boyd J, Collins A, Kennedy MC, Fairbairn N & McNeil R 2018. Characterizing fentanyl-related overdoses and implications for overdose response: Findings from a rapid ethnographic study in Vancouver, Canada. Drug and Alcohol Dependence 193: 69–74

Meier B 2007. In guilty plea, OxyContin maker to pay $600 million. New York Times, 10 May.

Nechuta SJ, Tyndall BD, Mukhopadhyay S & McPheeters ML 2018. Sociodemographic factors, prescription history and opioid overdose deaths: A statewide analysis using linked PDMP and mortality data. Drug and Alcohol Dependence 190: 62–71

Nicholas R, Lee N and Roche A 2011. Pharmaceutical drug misuse problems in Australia: Complex issues, balanced responses. Adelaide: National Centre for Education and Training on Addiction (NCETA), Flinders University

Patterson E, Sullivan T & Ticehurst A 2018. Use and misuse of prescription drugs among police detainees. Trends & issues in crime and criminal justice no. 541.

Patterson E, Sullivan T, Ticehurst A & Bricknell S 2018. Drug use monitoring in Australia: 2015 and 2016 report on drug use among police detainees. Statistical Report no. 4. Canberra: Australian Institute of Criminology.

Peacock A et al. 2018. Australian drug trends 2018: Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, University of New South Wales

Portenoy RK & Foley KM 1986. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 25: 171–86

Redfield RR 2018. CDC Director’s media statement on US life expectancy. Media statement, 29 Nov.

Roxburgh A, Dobbins T, Degenhardt L & Peacock A 2018. Opioid-, amphetamine-, and cocaine-induced deaths in Australia: August 2018. Sydney: National Drug and Alcohol Research Centre, University of New South Wales

Roxburgh et al. 2017. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug and Alcohol Dependence 179: 291–298

Roxburgh A et al. 2013. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug and Alcohol Review 32(3): 269–275

Special Advisory Committee on the Epidemic of Opioid Overdoses 2018. National report: Apparent opioid-related deaths in Canada (January 2016 to June 2018). Ottawa: Public Health Agency of Canada

Substance Abuse and Mental Health Service Administration (SAMHSA) 2017. Prescription drug monitoring programs: A guide for healthcare providers. SAMHSA In Brief 10(1).

Sullivan T & Patterson E 2018. Fentanyl use by police detainees remains unchanged. Statistical Bulletin no. 13.

Unick GJ, Rosenblum D, Mars S & Ciccarone D 2013. Intertwined epidemics: National demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. PLoS ONE 8(2): e54496

Votaw VR, Wittenauer J, Connery HS, Weiss R & McHugh RK 2016. Perceived risk of heroin use among nonmedical prescription opioid users. Addictive Behaviours 65: 218–223